# SMART CARD: Metformin IR

**Card ID:** MED_DM_BIG_001
**Version:** 3.0
**Last Updated:** 2025-12-08

---

# ðŸ“± CONDENSED VIEW

> Essentials for everyday use.

## WHAT YOU'RE DOING
Taking Metformin twice daily to lower your blood sugar and protect your heart.

## WHY THIS MATTERS
**Your goal:** "I want to be around to meet my grandkids. I don't want to end up like my dad."

**Why prescribed:** First-choice diabetes medication. Lowers blood sugar, protects heart, no weight gain.

**Evidence:** Grade A - Proven effective over 60 years, reduces diabetes complications by 32%.

## HOW TO DO IT
1. Take one pill **with breakfast**
2. Take one pill **with dinner**
3. **Always eat food** when you take it
4. Swallow whole with water

ðŸ’¡ **Tip:** Keep pills next to your coffee maker or dinner plate.

## WHEN TO DO IT
Twice daily with meals. Every day, ongoing.

## WHAT TO WATCH FOR

ðŸ”´ **Call 911:** Trouble breathing, severe muscle pain, feeling very cold, slow heartbeat

ðŸŸ  **Call doctor:** Stomach problems not improving after 4 weeks, extreme tiredness

ðŸŸ¡ **Normal at first:** Upset stomach, loose stools (improves in 2-4 weeks)

## DIFFICULTY
â­â­â˜†â˜†â˜† **Easy** - Twice daily pill with meals

## ðŸ’¬ WE'LL CHECK IN WITH YOU

| When | What We'll Ask |
|------|----------------|
| Day 3 | How's your stomach? Taking with food? |
| Day 7 | Tolerating? Any barriers? |
| Day 14 | Ready to increase dose? |
| Month 1 | Adherence? Side effects? |
| Month 3 | A1c recheck - let's see progress! |

## COMMUNITY
â­ 4.2/5 | 72% still taking at 6 months | 65% reached their goal

---

# ðŸ“‹ EXPANDED VIEW

> Full details for clinicians, advanced users, and curious patients.

---

## WHO

**Patient:** Take as prescribed, report side effects, communicate barriers

**Care Team:**
- Prescriber: Prescribes, adjusts dose, monitors labs
- Pharmacist: Dispenses, counsels on use
- Nurse: Check-ins, education, troubleshooting

**Support People:**
- Family/caregiver: Reminders, watching for warning signs

---

## WHAT

**Medication:** Metformin Hydrochloride (Glucophage)
**Class:** Biguanide
**Dose:** 500mg â†’ titrating to 1000mg twice daily
**Form:** Oral tablet

---

## WHEN

**Schedule:** Twice daily with breakfast and dinner
**Duration:** Ongoing
**Missed dose:** Take with next meal. Don't double up.

### Dose Progression

| Week | Morning | Evening |
|------|---------|---------|
| 1-2 | 500mg | 500mg |
| 3-4 | 500mg | 1000mg |
| 5+ | 1000mg | 1000mg |

*Advance only when tolerating well.*

---

## WHERE

**Setting:** Home, with meals
**Storage:** Room temperature, away from moisture

---

## WHY

**Mechanism:**
1. Reduces liver glucose production
2. Improves muscle insulin sensitivity
3. Slows intestinal glucose absorption

**Benefits:** No hypoglycemia risk (monotherapy). Weight neutral or slight loss. Cardiovascular protection.

---

## HOW

### Instructions
1. Take with first bite of food (not before eating)
2. Swallow whole with water
3. Same times daily for consistency

### If Stomach Upset
- Eat more food with it
- Avoid greasy foods initially
- Usually resolves by week 3-4
- Extended-release option if persistent

---

## MEASURE

| Test | Frequency | Purpose |
|------|-----------|---------|
| A1c | q3mo â†’ q6mo when stable | 3-month glucose average |
| eGFR | q3-6mo initially | Kidney safety |
| B12 | Annually | Metformin lowers B12 |

**What you may notice:** More energy, fewer cravings, possible weight loss

---

## TARGET

**A1c goal:** Below 7.0%
**Timeline:** 3-6 months

**Expected results:**
- Glucose improving: 2-4 weeks
- Full A1c effect: 3 months
- Typical A1c reduction: 1.0-1.5%

---

## SAFETY

### Common Side Effects (Temporary)
- Stomach upset, nausea (30-50%)
- Diarrhea
- Metallic taste

### Contact Care Team If:
- GI symptoms persist >4 weeks
- Unusual tiredness
- Numbness/tingling extremities
- Scheduled for contrast imaging

### Emergency (Call 911):
- Trouble breathing
- Severe muscle pain
- Feeling very cold + slow heartbeat
- Severe stomach pain + vomiting

### Hold If:
- Severely dehydrated or acutely ill
- IV contrast (48h before/after)

### Interactions:
| Substance | Action |
|-----------|--------|
| Alcohol | Limit 1-2 drinks |
| NSAIDs | Use sparingly |
| IV contrast | Hold 48h |

---

## FOLLOW-UP

### Phase 1: Initiation (Days 1-14)
| Day | Method | Focus |
|-----|--------|-------|
| 3 | App/text | GI tolerance |
| 7 | App/phone | Barriers |
| 14 | App/phone | Dose advancement |

### Phase 2: Titration (Weeks 3-12)
| When | Method | Focus |
|------|--------|-------|
| Week 4 | Phone/visit | Dose increase |
| Week 8 | App | Adherence |
| Month 3 | Lab + visit | A1c recheck |

### Phase 3: Maintenance (Month 4+)
| When | Method | Focus |
|------|--------|-------|
| Monthly | App | Quick check |
| q3-6mo | Lab + visit | A1c, eGFR |
| Yearly | Comprehensive | B12, full review |

### Decision Tree:
| Situation | Action |
|-----------|--------|
| A1c at goal | Continue, extend intervals |
| A1c elevated after 3mo max dose | Add second agent |
| Persistent GI | Switch to ER formulation |
| eGFR declining | Adjust dose or discontinue |

---

## IF YOU'RE STRUGGLING

**Missed days?** Restart with next meal. No doubling.

**Missed week+?** Restart at current dose. Notify at next check-in.

### Barriers & Solutions

| Barrier | Solution |
|---------|----------|
| Forgetting | Pill organizer, alarm, anchor to meals |
| GI issues | More food, wait 3-4 weeks, try ER |
| No perceived effect | Works silently - A1c shows it |
| Travel | Take with any meal; timing flexible |

---

## YOUR PROGRESS

**Baseline:** A1c: _____ | Date started: _____

**Milestones:**
- [ ] First week completed
- [ ] Target dose reached
- [ ] First A1c recheck
- [ ] A1c at goal

---

## EVIDENCE

### Summary
Metformin is the most extensively studied diabetes medication with over 60 years of clinical use. Multiple large trials and every major diabetes guideline recommend it as first-line therapy. It reliably lowers blood sugar and uniquely among diabetes drugs, has proven cardiovascular benefits.

### Grade: A

### Grading Criteria Met
- [x] Supported by multiple systematic reviews/meta-analyses
- [x] Multiple large, well-designed RCTs with consistent results
- [x] Endorsed by all major guideline bodies (ADA, EASD, AACE)
- [x] Extensive real-world effectiveness data
- [x] Benefits clearly outweigh risks

### Primary Sources

#### Guideline: ADA Standards of Care in Diabetes
- **Organization:** American Diabetes Association
- **Year:** 2024
- **Recommendation:** "Metformin is the preferred initial pharmacologic agent for type 2 diabetes"
- **Strength:** Strong (Level A)
- **Link:** diabetesjournals.org/care

#### Guideline: ADA/EASD Consensus Report
- **Organization:** American Diabetes Association / European Association for the Study of Diabetes
- **Year:** 2022
- **Recommendation:** "Metformin remains first-line therapy for most patients with T2DM"
- **Strength:** Strong consensus

#### Trial: UKPDS 34 (UK Prospective Diabetes Study)
- **Citation:** UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):854-865
- **Design:** Randomized controlled trial
- **Population:** Newly diagnosed T2DM, overweight patients
- **N:** 1,704
- **Follow-up:** Median 10.7 years
- **Key Findings:**
  - 32% reduction in diabetes-related endpoints (p=0.002)
  - 42% reduction in diabetes-related death (p=0.017)
  - 36% reduction in all-cause mortality (p=0.011)
- **NNT:** 14 (to prevent one diabetes-related endpoint over 10 years)
- **Limitations:** Overweight subgroup only; open-label design

#### Meta-Analysis: Cochrane Review
- **Citation:** Hirst JA, et al. Cochrane Database Syst Rev. 2012
- **Design:** Systematic review of 35 RCTs
- **Key Finding:** Metformin reduces HbA1c by ~1.0-1.5% vs placebo

### Supporting Evidence

**A1c Reduction:** Consistent 1.0-1.5% reduction across trials, effect maintained long-term

**Cardiovascular Outcomes:** UKPDS showed CV mortality benefit maintained at 10-year follow-up; HOME trial showed reduced macrovascular events

**Weight Effects:** Weight neutral to modest loss (-1-2 kg); does not cause hypoglycemia as monotherapy

**Safety Profile:** 60+ years post-marketing experience; lactic acidosis extremely rare (4.3 per 100,000 patient-years)

### Evidence Gaps
- Limited RCT data in patients with eGFR 30-45
- No large RCTs comparing to newer agents as first-line
- Optimal dosing for CV benefit not established

### Last Evidence Review
December 2024

---

## NOTES

### Feasibility Score (Clinician Reference): 75/100
- Base: 100
- Deductions: GI effects (-15), BID dosing (-5), monitoring (-5)
- Boosters: Affordable (+10), no hypoglycemia (+5), weight neutral (+5)

### Patient Confidence Assessment
Ask: "On a scale of 0-10, how confident are you that you can take this medication twice daily with meals?"
- 8-10: Ready to start
- 5-7: Explore barriers
- 0-4: Address concerns first

### Version History
- v3.0 (2025-12-08): Restructured for patient/clinician clarity; robust EVIDENCE section
- v2.5 (2025-12-07): Added AI agent specifications
- v1.0 (2024-11-23): Initial card

---

# ðŸ”§ AI METADATA

<!--
Hidden from user interface.
Parsed by AI agents for decision-making.
Clinician override via interface dropdown.
-->

```yaml
# === IDENTIFIERS ===
card_id: MED_DM_BIG_001
generic: Metformin Hydrochloride
brand: Glucophage
class: Biguanide
path: Medical > Medications > Diabetes > Biguanides

# === AUTONOMY ===
autonomy:
  tier: 4  # Clinician-directed
  responsible_agent: AI_Pharmacist
  specialist_consult: AI_Endocrinologist
  approval_type: individual
  patient_can_initiate: false
  patient_can_adjust: false
  patient_can_pause: true  # AI alerts clinician
  patient_can_discontinue: false  # Requires approval

# === TAGS ===
tags:
  clinical: [diabetes, T2DM, metabolic, first_line]
  evidence: [grade_A, guideline_recommended, RCT_supported]
  properties: [oral, BID, titratable, chronic]
  systems: [metabolic, cardiovascular]

# === RELATED CARDS ===
related:
  alternative: MED_DM_BIG_002  # Metformin ER - if GI intolerant
  add_on:
    - MED_DM_SGLT2_001  # Empagliflozin - if CV/renal benefit needed
    - MED_DM_GLP1_001   # Semaglutide - if weight loss priority
  synergy:
    - DIAG_LAB_A1C      # A1c monitoring
    - BEHAV_NUT_xxx     # Nutrition cards
    - BEHAV_MOV_xxx     # Movement cards
  prerequisite: none
  leads_to: [SGLT2i, GLP1]  # If inadequate response

# === DOSING ===
dosing:
  forms: [500mg, 850mg, 1000mg]
  route: PO
  frequency: BID
  with_food: required
  start: 500mg BID
  target: 1000mg BID
  max: 2550mg/day
  titration:
    interval: 1-2 weeks
    increment: 500mg

# === CONTRAINDICATIONS ===
contraindications:
  - eGFR < 30
  - lactic_acidosis_history
  - acute_decompensated_HF
  - severe_hepatic_impairment

# === ADJUSTMENTS ===
adjustments:
  renal:
    - condition: eGFR 30-45
      action: max 1000mg/day, monitor q3mo
    - condition: eGFR 45-60
      action: full dose, monitor q3mo
  age:
    - condition: age > 75
      action: start 500mg daily, slow titration
  GI_history:
    - condition: prior_intolerance
      action: start 500mg daily, consider ER

# === HOLD CONDITIONS ===
hold:
  - condition: IV_contrast
    action: hold 48h before and after
    auto_resume: yes, if eGFR stable
  - condition: acute_illness_dehydration
    action: hold until resolved
  - condition: surgery_NPO
    action: hold day of procedure

# === INTERACTIONS ===
interactions:
  - drug: alcohol
    severity: moderate
    action: counsel limit 1-2 drinks
  - drug: NSAIDs_chronic
    severity: moderate
    action: monitor eGFR
  - drug: contrast_IV
    severity: high
    action: hold protocol

# === MONITORING ===
monitoring:
  A1c: {initial: q3mo, stable: q6mo}
  eGFR: {initial: q3mo, stable: annually}
  B12: annually

# === ALERTS ===
alerts:
  efficacy:
    - condition: A1c drop < 0.5% after 3mo max dose
      action: recommend add second agent
      urgency: routine
  safety:
    - condition: eGFR decline > 25%
      action: flag for clinician review
      urgency: urgent
    - condition: eGFR < 30
      action: discontinue, alert clinician
      urgency: urgent
  tolerability:
    - condition: GI symptoms > 4 weeks
      action: recommend switch to ER
      urgency: routine
  adherence:
    - condition: missed 3+ consecutive
      action: barrier assessment
      urgency: routine
    - condition: adherence < 50% over 14 days
      action: escalate to care team
      urgency: soon

# === PROACTIVE CHECK-INS ===
checkins:
  initiation:
    - day: 3
      questions: [gi_tolerance, taking_with_food]
      escalate_if: severe_gi
    - day: 7
      questions: [tolerating, barriers]
      escalate_if: persistent_gi, non_adherence
    - day: 14
      questions: [ready_to_advance]
      action_if_ready: advance_dose
  titration:
    - week: 4
      focus: dose_advancement
    - week: 8
      focus: adherence_check
  maintenance:
    - interval: monthly
      focus: adherence_symptoms
    - interval: quarterly
      focus: a1c_egfr_comprehensive

# === LIFECYCLE ===
lifecycle:
  initiation:
    duration: days 1-14
    focus: tolerability
    success: tolerating BID, no severe GI
  maintenance:
    adherence_target: 80%
    review: monthly app, quarterly visit
  de_loading:
    graduation:
      criteria: A1c < 5.7% sustained 6mo + lifestyle
      action: supervised taper
      rare: true
    transition_gi:
      criteria: GI intolerable > 4 weeks
      action: switch to MED_DM_BIG_002
    transition_efficacy:
      criteria: A1c not at goal after 3mo max dose
      action: add SGLT2i or GLP-1
    discontinue:
      criteria: [eGFR < 30, lactic_acidosis, patient_refusal]
      action: stop, document, alternative

# === EVIDENCE (AI Reference) ===
evidence:
  grade: A
  last_reviewed: 2024-12
  primary_guideline: ADA_Standards_2024
  key_trials: [UKPDS_34, HOME]
  meta_analyses: [Cochrane_2012]
  evidence_gaps: [eGFR_30-45_RCT, first_line_vs_newer_agents]

# === FEASIBILITY ===
feasibility:
  score: 75
  difficulty: easy  # Patient-facing
  deductions: {GI_effects: -15, BID_dosing: -5, monitoring: -5}
  boosters: {affordable: +10, no_hypoglycemia: +5, weight_neutral: +5}
```

---

**END OF CARD**

*Template: Universal Card Template v3.0*
